Lancelot Technology:
CORCYM , the medical device company dedicated to providing patients and cardiac surgeons with the best solutions to fight structural heart disease, announces today the integration of LANCELOT technologies into Perceval Plus after recent approval from the U.S. regulatory agency FDA, Food & Drug Administration.
“For many years, Perceval has been well-known as the only sutureless valve designed to simplify surgical implantation, reducing the impact of surgery with faster patient recovery[1][2]. We expect LANCELOT technologies to take it a step further, delivering the next generation of reproducibility and consistency in valve performance for cardiac surgeons and their patients around the world,” said Christian Mazzi, CORCYM CEO.
LANCELOT has demonstrated excellent performance[3]. A CO2 Laser cuts the pericardium and pre-sets the sutures. The leaflets are shaped in a zero-pressure process that preserves tissue integrity and optimizes the symmetry of the leaflets to boost the mechanical properties and stability of the tissue, achieving consistency and reproducibility.
“We at CORCYM are committed to helping cardiac surgeons excel and treat their patients better today and in the future, worldwide. We are pleased to bring these new surgical aortic valve technologies as a treatment option to patients in the U.S.,” added Mazzi.
